Table 1B Characteristics of the individual studies stratified by disease, ANCA type, and organ involvement.
| Subgroup | Sample Sizes | Allele for Cases | Allele for Controls | ||||
|---|---|---|---|---|---|---|---|
| Case | Control | Total | G | A | G | A | |
| GPA | 416 | 2522 | 2938 | 725 | 107 | 4672 | 372 |
| MPA | 212 | 2123 | 2335 | 382 | 42 | 3954 | 292 |
| PR3 | 200 | 2123 | 2323 | 355 | 45 | 3954 | 292 |
| MPO | 125 | 2123 | 2248 | 223 | 27 | 3954 | 292 |
| Lung | 202 | 2123 | 2325 | 360 | 44 | 3954 | 292 |
| ENT | 188 | 2123 | 2311 | 331 | 45 | 3954 | 292 |
| Skin | 92 | 2123 | 2215 | 154 | 30 | 3954 | 292 |
| Peripheral neuropathy | 98 | 2123 | 2221 | 168 | 28 | 3954 | 292 |
| Kidney | 278 | 2123 | 2401 | 504 | 52 | 3954 | 292 |
Jagiello, et al (2005), Martorana, et al (2012), Cao, et al (2012) were available for GPA subgroup. Martorana and Cao were available for MPA, PR3, MPO, lung, ENT, skin, peripheral neuropathy, and kidney subgroups. HWE: Hardy-Weinberg equilibrium; ANCA: antineutrophil cytoplasmic antibody; GPA: granulomatosis with polyangiitis (Wegener’s); MPA: microscopic polyangiitis; PR3: proteinase 3; MPO: myeloperoxidase.